PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 52 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,210,000 | -70.5% | 1,674,690 | -41.6% | 0.00% | -100.0% |
| Q4 2021 | $7,490,000 | -40.2% | 2,869,650 | -28.7% | 0.00% | -50.0% |
| Q3 2021 | $12,517,000 | -25.9% | 4,024,658 | -11.3% | 0.00% | -33.3% |
| Q2 2021 | $16,889,000 | +2.3% | 4,539,897 | -4.9% | 0.00% | 0.0% |
| Q1 2021 | $16,513,000 | +213.5% | 4,772,918 | +204.5% | 0.00% | +200.0% |
| Q4 2020 | $5,268,000 | -54.9% | 1,567,656 | -52.9% | 0.00% | -50.0% |
| Q3 2020 | $11,686,000 | -36.7% | 3,329,262 | -17.1% | 0.00% | -50.0% |
| Q2 2020 | $18,474,000 | +38.6% | 4,016,229 | -0.3% | 0.00% | 0.0% |
| Q1 2020 | $13,330,000 | -43.9% | 4,027,284 | +3.5% | 0.00% | -20.0% |
| Q4 2019 | $23,782,000 | +45.8% | 3,892,256 | -0.5% | 0.01% | +25.0% |
| Q3 2019 | $16,316,000 | -68.1% | 3,912,727 | +0.4% | 0.00% | -63.6% |
| Q2 2019 | $51,105,000 | +56.7% | 3,895,213 | +13.6% | 0.01% | +57.1% |
| Q1 2019 | $32,617,000 | +213.1% | 3,429,779 | +1.7% | 0.01% | +133.3% |
| Q4 2018 | $10,416,000 | – | 3,370,960 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |